About: Avax Technologies

An Entity of Type: Public company, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Avax Technologies, Inc is a Philadelphia-based biotechnology company whose most advanced product candidate is MVax for melanoma. MVax is a cancer vaccine that received a Special Protocol Assessment agreement with the FDA in October 2006, and subsequently began a Phase III registration clinical trial in November 2007. In previous studies, MVax demonstrated a 5-year overall survival rate (OS)of 44% and response rate of 35% (13% CR, 22% PR).

thumbnail
Property Value
dbo:abstract
  • Avax Technologies, Inc is a Philadelphia-based biotechnology company whose most advanced product candidate is MVax for melanoma. MVax is a cancer vaccine that received a Special Protocol Assessment agreement with the FDA in October 2006, and subsequently began a Phase III registration clinical trial in November 2007. In previous studies, MVax demonstrated a 5-year overall survival rate (OS)of 44% and response rate of 35% (13% CR, 22% PR). (en)
dbo:industry
dbo:keyPerson
dbo:service
dbo:thumbnail
dbo:type
dbo:wikiPageExternalLink
dbo:wikiPageID
  • 25516263 (xsd:integer)
dbo:wikiPageLength
  • 6014 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID
  • 1106783632 (xsd:integer)
dbo:wikiPageWikiLink
dbp:homepage
dbp:industry
dbp:keyPeople
  • (en)
  • Richard Rainey (en)
dbp:locationCity
dbp:locationCountry
dbp:logo
  • Avax Logo.PNG (en)
dbp:name
  • Avax Technologies (en)
dbp:products
  • AC Vaccine (en)
dbp:services
dbp:subsid
  • Genopoietic SA (en)
dbp:type
dbp:wikiPageUsesTemplate
dcterms:subject
gold:hypernym
rdf:type
rdfs:comment
  • Avax Technologies, Inc is a Philadelphia-based biotechnology company whose most advanced product candidate is MVax for melanoma. MVax is a cancer vaccine that received a Special Protocol Assessment agreement with the FDA in October 2006, and subsequently began a Phase III registration clinical trial in November 2007. In previous studies, MVax demonstrated a 5-year overall survival rate (OS)of 44% and response rate of 35% (13% CR, 22% PR). (en)
rdfs:label
  • Avax Technologies (en)
owl:sameAs
prov:wasDerivedFrom
foaf:depiction
foaf:homepage
foaf:isPrimaryTopicOf
foaf:name
  • Avax Technologies (en)
is dbo:wikiPageDisambiguates of
is dbo:wikiPageRedirects of
is dbo:wikiPageWikiLink of
is foaf:primaryTopic of
Powered by OpenLink Virtuoso    This material is Open Knowledge     W3C Semantic Web Technology     This material is Open Knowledge    Valid XHTML + RDFa
This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License